Financials data is unavailable for this security.
View more
Year on year Crescita Therapeutics Inc 's revenues fell -25.52% from 23.53m to 17.52m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 862.00k to a loss of 1.99m.
Gross margin | 54.66% |
---|---|
Net profit margin | -17.72% |
Operating margin | -16.77% |
Return on assets | -12.06% |
---|---|
Return on equity | -15.79% |
Return on investment | -15.07% |
More ▼
Cash flow in CADView more
In 2023, Crescita Therapeutics Inc increased its cash reserves by 13.92%, or 1.15m. The company earned 2.08m from its operations for a Cash Flow Margin of 11.85%. In addition the company used 133.00k on investing activities and also paid 782.00k in financing cash flows.
Cash flow per share | -0.0775 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.8861 |
---|---|
Tangible book value per share | 0.7813 |
More ▼
Balance sheet in CADView more
Current ratio | 3.37 |
---|---|
Quick ratio | 2.32 |
Total debt/total equity | 0.0603 |
---|---|
Total debt/total capital | 0.0568 |
More ▼
Growth rates in CAD
SmartText is unavailable
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -510.59 |